TMPRSS2 and neoplasm: In nearly 50%–60% of fusion-positive tumours, this results from an intronic deletion on chromosome 21, which deletes the genomic region between TMPRSS2 and ERG. Alternatively, complicated genomic rearrangements involving chromosome 21q22 and other chromosomes may also give this fusion (35–37).